The final proof of the IL-17 centrality is represented by the striking efficacy obtained by IL-17 antagonists and IL-17 receptor A subunit blocker in reverting clinical, histologic, and molecular features of the psoriasis phenotype in more than 80% of treated patients [11]. Here, IL17A is linked to psoriasis.